ArticleStroke (Hoboken, N.J.)2026
Impact of Aneurysm Size and Flow Diverter Use on Outcomes After Endovascular Therapy of Unruptured Paraclinoid Aneurysms.
Article in Stroke (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFlow diverters (FDs) are increasingly used for unruptured paraclinoid aneurysms, especially large or giant ones. However, their benefit over conventional endovascular therapy remains unclear. This study evaluated outcomes after endovascular therapy of unruptured paraclinoid aneurysms, with aneurysm size as the primary exposure, and further examined the modifying effect of FD use.
methodsWe analyzed data of patients with unruptured paraclinoid aneurysms from the Japanese Registry of Neuroendovascular Therapy 4, a nationwide, multicenter registry enrolling patients who underwent endovascular therapy in 166 Japanese institutions from 2015 to 2019. The primary outcome was worsening in the modified Rankin Scale score ≥1 at 30 days. Secondary outcomes included ischemic and hemorrhagic complications. Outcomes were compared by aneurysm size (<10 mm versus ≥10 mm) and further stratified by FD use.
resultsOf 3860 patients (3326 women, median age 59 years), 3048 had aneurysms <10 mm and 776 had aneurysms ≥10 mm. FD use was more common in aneurysms ≥10 mm (64.2% versus 3.0%). Worsening in modified Rankin Scale score occurred in 5.3% with aneurysms ≥10 mm versus 2.0% with <10 mm (adjusted odds ratio, 2.28 [95% CI, 1.48-3.49]). Ischemic complications were more frequent with larger aneurysms (5.7% versus 4.0%,
conclusionsEndovascular embolization of unruptured paraclinoid aneurysms ≥10 mm was associated with a higher morbidity compared with aneurysms <10 mm. FD use may reduce ischemic complications in larger aneurysms; however, this benefit was not clearly reflected in 30-day functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.